Is IL-6 a key cytokine target for therapy in COVID-19?
The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid development of clinical trials targeting this cytokine. Overall, these trials do not support the widespread use of IL-6 antagonists in hospitalized patients with mild-to-moderate disease, but IL-6 antagonist...
Gespeichert in:
| Veröffentlicht in: | Nature reviews. Immunology 2021-06, Vol.21 (6), p.337-339 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 339 |
|---|---|
| container_issue | 6 |
| container_start_page | 337 |
| container_title | Nature reviews. Immunology |
| container_volume | 21 |
| creator | Jones, Simon A. Hunter, Christopher A. |
| description | The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid development of clinical trials targeting this cytokine. Overall, these trials do not support the widespread use of IL-6 antagonists in hospitalized patients with mild-to-moderate disease, but IL-6 antagonists may be beneficial when rapidly deployed in patients with severe COVID-19, as we discuss here. |
| doi_str_mv | 10.1038/s41577-021-00553-8 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8043092</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A663935036</galeid><sourcerecordid>A663935036</sourcerecordid><originalsourceid>FETCH-LOGICAL-c655t-ca490404e952a62c6eef4e938b3e6056eb89abe698e04f523f9100aff48554863</originalsourceid><addsrcrecordid>eNp9kl1rFDEUhgex2Fr9A15IQBB7MTWZfEzmRilrrQMLBb9uQ3Z6Mpt2NlmTjLj_3qxb1x0RyUU-zvO-SQ5vUTwj-JxgKl9HRnhdl7giJcac01I-KE4Iq1lJakYe7teUHhePY7zFmIhceVQcUyo5plV9Uog2onZeCqTRHWxQt0n-zjpASYceEjI-oLSEoNcbZB2aXX9t35WkefukODJ6iPD0fj4tvry__Dz7UM6vr9rZxbzsBOep7DRrMMMMGl5pUXUCwOQNlQsKAnMBC9noBYhGAmaGV9Q0BGNtDJOcMynoafFm57seFyu46cCloAe1Dnalw0Z5bdW04uxS9f67kphR3FTZ4NW9QfDfRohJrWzsYBi0Az9GVXFS1bQWbIu--Au99WNw-XuZooIQ3IgDqtcDKOuMz_d2W1N1IQRtaG7s9t3n_6DyuIGV7bwDY_P5RHA2EWQmwY_U6zFG1X76OGVfHrBL0ENaRj-MyXoXp2C1A7vgYwxg9o0jWG0jpHYRUjlC6leElMyi54ct30t-ZyYDdAfEXHI9hD99-o_tTwDKyrk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2536110962</pqid></control><display><type>article</type><title>Is IL-6 a key cytokine target for therapy in COVID-19?</title><source>MEDLINE</source><source>SpringerLink Journals</source><source>Nature Journals Online</source><creator>Jones, Simon A. ; Hunter, Christopher A.</creator><creatorcontrib>Jones, Simon A. ; Hunter, Christopher A.</creatorcontrib><description>The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid development of clinical trials targeting this cytokine. Overall, these trials do not support the widespread use of IL-6 antagonists in hospitalized patients with mild-to-moderate disease, but IL-6 antagonists may be beneficial when rapidly deployed in patients with severe COVID-19, as we discuss here.</description><identifier>ISSN: 1474-1733</identifier><identifier>EISSN: 1474-1741</identifier><identifier>DOI: 10.1038/s41577-021-00553-8</identifier><identifier>PMID: 33850327</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/250/127/1213 ; 631/326/596/4130 ; 692/308/575 ; 692/420/254 ; 692/699/255/2514 ; Antagonists ; Anti-inflammatory drugs ; Antibodies, Monoclonal, Humanized - adverse effects ; Antibodies, Monoclonal, Humanized - therapeutic use ; Biological response modifiers ; Biomedical and Life Sciences ; Biomedicine ; Clinical trials ; Comment ; Coronaviruses ; COVID-19 ; COVID-19 - complications ; COVID-19 - immunology ; COVID-19 Drug Treatment ; Cytokine Release Syndrome - drug therapy ; Cytokine Release Syndrome - etiology ; Cytokine Release Syndrome - immunology ; Cytokines ; Cytokines - antagonists & inhibitors ; Health aspects ; Humans ; Immune response ; Immunological research ; Immunology ; Interleukin 6 ; Interleukin-6 - antagonists & inhibitors ; Interleukin-6 - blood ; Methods ; Molecular targeted therapy ; Receptors, Interleukin-6 - antagonists & inhibitors ; SARS-CoV-2 ; Severity of Illness Index ; Signal Transduction - drug effects ; Signal Transduction - immunology</subject><ispartof>Nature reviews. Immunology, 2021-06, Vol.21 (6), p.337-339</ispartof><rights>Springer Nature Limited 2021</rights><rights>COPYRIGHT 2021 Nature Publishing Group</rights><rights>Springer Nature Limited 2021.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c655t-ca490404e952a62c6eef4e938b3e6056eb89abe698e04f523f9100aff48554863</citedby><cites>FETCH-LOGICAL-c655t-ca490404e952a62c6eef4e938b3e6056eb89abe698e04f523f9100aff48554863</cites><orcidid>0000-0001-7297-9711</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1038/s41577-021-00553-8$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1038/s41577-021-00553-8$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>230,314,776,780,881,27901,27902,41464,42533,51294</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33850327$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jones, Simon A.</creatorcontrib><creatorcontrib>Hunter, Christopher A.</creatorcontrib><title>Is IL-6 a key cytokine target for therapy in COVID-19?</title><title>Nature reviews. Immunology</title><addtitle>Nat Rev Immunol</addtitle><addtitle>Nat Rev Immunol</addtitle><description>The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid development of clinical trials targeting this cytokine. Overall, these trials do not support the widespread use of IL-6 antagonists in hospitalized patients with mild-to-moderate disease, but IL-6 antagonists may be beneficial when rapidly deployed in patients with severe COVID-19, as we discuss here.</description><subject>631/250/127/1213</subject><subject>631/326/596/4130</subject><subject>692/308/575</subject><subject>692/420/254</subject><subject>692/699/255/2514</subject><subject>Antagonists</subject><subject>Anti-inflammatory drugs</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Antibodies, Monoclonal, Humanized - therapeutic use</subject><subject>Biological response modifiers</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Clinical trials</subject><subject>Comment</subject><subject>Coronaviruses</subject><subject>COVID-19</subject><subject>COVID-19 - complications</subject><subject>COVID-19 - immunology</subject><subject>COVID-19 Drug Treatment</subject><subject>Cytokine Release Syndrome - drug therapy</subject><subject>Cytokine Release Syndrome - etiology</subject><subject>Cytokine Release Syndrome - immunology</subject><subject>Cytokines</subject><subject>Cytokines - antagonists & inhibitors</subject><subject>Health aspects</subject><subject>Humans</subject><subject>Immune response</subject><subject>Immunological research</subject><subject>Immunology</subject><subject>Interleukin 6</subject><subject>Interleukin-6 - antagonists & inhibitors</subject><subject>Interleukin-6 - blood</subject><subject>Methods</subject><subject>Molecular targeted therapy</subject><subject>Receptors, Interleukin-6 - antagonists & inhibitors</subject><subject>SARS-CoV-2</subject><subject>Severity of Illness Index</subject><subject>Signal Transduction - drug effects</subject><subject>Signal Transduction - immunology</subject><issn>1474-1733</issn><issn>1474-1741</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp9kl1rFDEUhgex2Fr9A15IQBB7MTWZfEzmRilrrQMLBb9uQ3Z6Mpt2NlmTjLj_3qxb1x0RyUU-zvO-SQ5vUTwj-JxgKl9HRnhdl7giJcac01I-KE4Iq1lJakYe7teUHhePY7zFmIhceVQcUyo5plV9Uog2onZeCqTRHWxQt0n-zjpASYceEjI-oLSEoNcbZB2aXX9t35WkefukODJ6iPD0fj4tvry__Dz7UM6vr9rZxbzsBOep7DRrMMMMGl5pUXUCwOQNlQsKAnMBC9noBYhGAmaGV9Q0BGNtDJOcMynoafFm57seFyu46cCloAe1Dnalw0Z5bdW04uxS9f67kphR3FTZ4NW9QfDfRohJrWzsYBi0Az9GVXFS1bQWbIu--Au99WNw-XuZooIQ3IgDqtcDKOuMz_d2W1N1IQRtaG7s9t3n_6DyuIGV7bwDY_P5RHA2EWQmwY_U6zFG1X76OGVfHrBL0ENaRj-MyXoXp2C1A7vgYwxg9o0jWG0jpHYRUjlC6leElMyi54ct30t-ZyYDdAfEXHI9hD99-o_tTwDKyrk</recordid><startdate>20210601</startdate><enddate>20210601</enddate><creator>Jones, Simon A.</creator><creator>Hunter, Christopher A.</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>3V.</scope><scope>7QR</scope><scope>7RV</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7N</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-7297-9711</orcidid></search><sort><creationdate>20210601</creationdate><title>Is IL-6 a key cytokine target for therapy in COVID-19?</title><author>Jones, Simon A. ; Hunter, Christopher A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c655t-ca490404e952a62c6eef4e938b3e6056eb89abe698e04f523f9100aff48554863</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>631/250/127/1213</topic><topic>631/326/596/4130</topic><topic>692/308/575</topic><topic>692/420/254</topic><topic>692/699/255/2514</topic><topic>Antagonists</topic><topic>Anti-inflammatory drugs</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Antibodies, Monoclonal, Humanized - therapeutic use</topic><topic>Biological response modifiers</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Clinical trials</topic><topic>Comment</topic><topic>Coronaviruses</topic><topic>COVID-19</topic><topic>COVID-19 - complications</topic><topic>COVID-19 - immunology</topic><topic>COVID-19 Drug Treatment</topic><topic>Cytokine Release Syndrome - drug therapy</topic><topic>Cytokine Release Syndrome - etiology</topic><topic>Cytokine Release Syndrome - immunology</topic><topic>Cytokines</topic><topic>Cytokines - antagonists & inhibitors</topic><topic>Health aspects</topic><topic>Humans</topic><topic>Immune response</topic><topic>Immunological research</topic><topic>Immunology</topic><topic>Interleukin 6</topic><topic>Interleukin-6 - antagonists & inhibitors</topic><topic>Interleukin-6 - blood</topic><topic>Methods</topic><topic>Molecular targeted therapy</topic><topic>Receptors, Interleukin-6 - antagonists & inhibitors</topic><topic>SARS-CoV-2</topic><topic>Severity of Illness Index</topic><topic>Signal Transduction - drug effects</topic><topic>Signal Transduction - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jones, Simon A.</creatorcontrib><creatorcontrib>Hunter, Christopher A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Chemoreception Abstracts</collection><collection>Nursing & Allied Health Database</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Nature reviews. Immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jones, Simon A.</au><au>Hunter, Christopher A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Is IL-6 a key cytokine target for therapy in COVID-19?</atitle><jtitle>Nature reviews. Immunology</jtitle><stitle>Nat Rev Immunol</stitle><addtitle>Nat Rev Immunol</addtitle><date>2021-06-01</date><risdate>2021</risdate><volume>21</volume><issue>6</issue><spage>337</spage><epage>339</epage><pages>337-339</pages><issn>1474-1733</issn><eissn>1474-1741</eissn><abstract>The identification of elevated IL-6 levels in patients with severe COVID-19 led to the rapid development of clinical trials targeting this cytokine. Overall, these trials do not support the widespread use of IL-6 antagonists in hospitalized patients with mild-to-moderate disease, but IL-6 antagonists may be beneficial when rapidly deployed in patients with severe COVID-19, as we discuss here.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>33850327</pmid><doi>10.1038/s41577-021-00553-8</doi><tpages>3</tpages><orcidid>https://orcid.org/0000-0001-7297-9711</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1474-1733 |
| ispartof | Nature reviews. Immunology, 2021-06, Vol.21 (6), p.337-339 |
| issn | 1474-1733 1474-1741 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8043092 |
| source | MEDLINE; SpringerLink Journals; Nature Journals Online |
| subjects | 631/250/127/1213 631/326/596/4130 692/308/575 692/420/254 692/699/255/2514 Antagonists Anti-inflammatory drugs Antibodies, Monoclonal, Humanized - adverse effects Antibodies, Monoclonal, Humanized - therapeutic use Biological response modifiers Biomedical and Life Sciences Biomedicine Clinical trials Comment Coronaviruses COVID-19 COVID-19 - complications COVID-19 - immunology COVID-19 Drug Treatment Cytokine Release Syndrome - drug therapy Cytokine Release Syndrome - etiology Cytokine Release Syndrome - immunology Cytokines Cytokines - antagonists & inhibitors Health aspects Humans Immune response Immunological research Immunology Interleukin 6 Interleukin-6 - antagonists & inhibitors Interleukin-6 - blood Methods Molecular targeted therapy Receptors, Interleukin-6 - antagonists & inhibitors SARS-CoV-2 Severity of Illness Index Signal Transduction - drug effects Signal Transduction - immunology |
| title | Is IL-6 a key cytokine target for therapy in COVID-19? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-09T22%3A34%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Is%20IL-6%20a%20key%20cytokine%20target%20for%20therapy%20in%20COVID-19?&rft.jtitle=Nature%20reviews.%20Immunology&rft.au=Jones,%20Simon%20A.&rft.date=2021-06-01&rft.volume=21&rft.issue=6&rft.spage=337&rft.epage=339&rft.pages=337-339&rft.issn=1474-1733&rft.eissn=1474-1741&rft_id=info:doi/10.1038/s41577-021-00553-8&rft_dat=%3Cgale_pubme%3EA663935036%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2536110962&rft_id=info:pmid/33850327&rft_galeid=A663935036&rfr_iscdi=true |